Scholar Rock Holding
Open
$46.22
Prev. Close
$46.19
High
$46.22
Low
$46.22
Market Snapshot
$4.72B
-12.5
-2.46
289
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
emptyResult
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
Recently from Cashu
Scholar Rock Holding Boosts Workforce with Equity Awards for Innovative Therapy Development
Scholar Rock Strengthens Workforce with New Equity Awards Amidst Innovative Pipeline Development Scholar Rock Holding Corporation, a late-stage biopharmaceutical company based in Cambridge, Massachuse…
Scholar Rock Holding: Pioneering Innovative Therapies for Serious Diseases and Patient Care
### Scholar Rock Advances Innovative Therapeutics for Serious Diseases Scholar Rock Holding, a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on pioneering treatments…
Scholar Rock Holding Develops Innovative Therapies for Serious Diseases and Unmet Medical Needs
Scholar Rock Advances Novel Therapeutics for Serious Diseases Scholar Rock Holding, a late-stage biopharmaceutical firm based in Cambridge, Massachusetts, is making strides in developing innovative tr…
Scholar Rock Holding Appoints New Leadership Amid Regulatory Progress for SMA Treatment
Scholar Rock Strengthens Leadership Amid Regulatory Milestones Scholar Rock Holding, a late-stage biopharmaceutical company dedicated to innovative treatments for spinal muscular atrophy (SMA) and oth…